PUBLIC COMPANY
saveKite Pharma Inc
updated 2mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Foghorn cuts 40% of workforceFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 1d ago
- Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagonCellectis may have kicked off the year promising “huge momentum” in the allogeneic CAR-T space, but even the French biotech has been unable to resist the dominance of in vivo options.fiercebiotech · 19d ago
- CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’Following a steady stream of acquisitions that culminated in three biotech buyouts earlier this year, Gilead has now reached “critical mass” in its efforts to diversify into oncology and inflammati…fiercebiotech · 24d ago
- ArsenalBio sheds most of staff in pivot to in vivo CAR-TAbout a year after halving its staff in a clinical push, Arsenal Biosciences is now making a hard pivot that involves laying off most of its employees and seeking out new homes for its assets.fiercebiotech · 1mo ago
- Study of Yescarta patients reveals genetic red flags for CAR-T therapy side effectsA new analysis of patients who took part in clinical trials for Kite Pharma’s CAR-T cell therapy Yescarta has revealed genetic signatures of toxicity risk, potentially providing a path forward for…fiercebiotech · 2mo ago
- Allogene CEO to step down; Agios drug fails key testDavid Chang will leave his post after an eight-year run at the cell therapy maker. Elsewhere, a next-generation blood disease drug stumbled and an acquisition yielded an FDA approval for AbbVie.biopharma_dive · 4mo ago
comments(0)
5-min edit window · permanent after that